🔴 Mirum Pharmaceuticals is trading 4.1% down with no verified company-specific catalyst

Mirum Pharmaceuticals is trading 4.06% down at $86.06, with no verified company-specific announcement explaining the decline.

• The company had scheduled a September 28 investor call to share Phase 3 AZURE-1 topline results for brelovitug and 48-week Phase 2b data.
• Broader markets were weak: the S&P 500 fell 0.53% and Nasdaq fell 0.72%.
• Reuters reported oil rose and bond yields climbed amid inflation concerns; this backdrop may have contributed, but evidence does not establish it as the direct cause.